Last updated on June 2019

Safety Tolerability Pharmacokinetics and Activity of K0706


Brief description of study

Phase 1/2 study to determine safety, tolerability, pharmacokinetics and activity of K0706

Detailed Study Description

Part A ( for Healthy volunteers) of the study is completed Part B (for CML subject ) of the study is ongoing. (Recruitment for Part B initiated in April 2017) Part C of study in subjects with CML and Ph+ ALL is on-going. (Open for Recruitment )

Clinical Study Identifier: NCT02629692

Find a site near you

Start Over

SPARC Site 19

Glendale, CA United States
  Connect »

SPARC Site 20

Los Angeles, CA United States
  Connect »

SPARC Site 31

New York, NY United States
  Connect »

SPARC Site 23

Valhalla, NY United States
  Connect »

SPARC Site 22

Charleston, SC United States
  Connect »

SPARC Site 24

Dallas, TX United States
  Connect »

SPARC Site 21

Houston, TX United States
  Connect »

SPARC Site 33

Salt Lake City, UT United States
  Connect »

SPARC Site 32

Seattle, WA United States
  Connect »

SPARC Site 2

Antwerpen, Belgium
  Connect »

SPARC Site 1

Leuven, Belgium
  Connect »

SPARC Site 3

Praha 10, Czechia
  Connect »

SPARC Site 4

Marseille Cedex 9, France
  Connect »

SPARC Site 7

Pierre-Bénite, France
  Connect »

SPARC Site 6

Toulouse Cedex 9, France
  Connect »

SPARC Site 5

Tours Cedex 9, France
  Connect »

SPARC Site 12

Hyderabad, India
  Connect »

SPARC Site 25

Seoul, Korea, Republic of
  Connect »

SPARC Site 30

London, United Kingdom
  Connect »

SPARC Site 18

London, United Kingdom
  Connect »

SPARC Site 7

Pierre-Bénite, France
  Connect »

SPARC Site 7

Pierre-Bénite, France
  Connect »

SPARC Site 7

Pierre-Bénite, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.